U.S. markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
43.40+0.10 (+0.23%)
At close: 4:00PM EDT

43.40 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close43.30
Bid43.27 x 800
Ask47.09 x 1200
Day's Range42.48 - 43.92
52 Week Range27.77 - 56.75
Avg. Volume651,967
Market Cap2.999B
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-5.21
Earnings DateOct 29, 2020 - Nov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

    CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.About Agios Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.ContactsInvestors: Holly Manning, 617-844-6630 Director, Investor Relations Holly.Manning@agios.comMedia: Jessica Rennekamp, 857-209-3286 Associate Director, Corporate Communications Jessica.Rennekamp@agios.com

  • Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript
    Motley Fool

    Agios Pharmaceuticals Inc (AGIO) Q2 2020 Earnings Call Transcript

    With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial and Global Marketing; and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Development. Dr. Bruce Car, our Chief Scientific Officer will join for Q&A.

  • Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates

    Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?